The present invention relates to novel compounds of formula (I): wherein -- represents a single or a double bond; R is a radical selected from: in which R.sub.1 is halogen, cyano, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl or trifluoromethoxy and p is zero or an integer from 1 to 3; R.sub.2 is hydrogen or C.sub.1-4 alkyl; R.sub.3 is hydrogen, hydroxy or C.sub.1-4 alkyl; R.sub.4 is hydrogen or R.sub.4 together with R.sub.3 represents .dbd.O or .dbd.CH2; R.sub.5 is phenyl, naphthyl, a 9 to 10 membered fused bicyclic heterocyclic group or a 5 or 6 membered heteroaryl group, wherein said groups are optionally substituted by 1 to 3 groups independently selected from trifluoromethyl, C.sub.1-4 alkyl, hydroxy, cyano, C.sub.1-4 alkoxy, trifluoromethoxy, halogen or S(O)qC.sub.1-4 alkyl; R.sub.6 and R.sub.7 independently are hydrogen, cyano, C.sub.1-4 alkyl; R.sub.8 is (CH.sub.2)rR.sub.10; R.sub.9 is hydrogen, halogen, C.sub.3-7 cycloalkyl, hydroxy, nitro, cyano or C.sub.1-4 alkyl optionally substituted by one or two groups selected from halogen, cyano, hydroxy or C.sub.1-4 alkoxy; R.sub.10 is hydrogen or C.sub.3-7 cycloalkyl; n is 1 or 2; q is 0, 1 or 2; r is 0 or an integer from 1 to 4;or a pharmaceutically acceptable salt or a solvate thereof, process for their preparation and their use in the treatment of conditions mediated by tackykinins and/or by selective inhibition of the serotonin reuptake transporter protein